Study S000474

Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06657209
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: RECRUITING
Enrollment: 104
Start: 2025-01-13
Primary completion: 2027-12-15
Lead sponsor: Stanford University
Conditions: Diabetes Mellitus, Type 2; Diabetes; Type 2 Diabetes; Pre Diabetes
Interventions: PROCEDURE:Insulin resistance testing; PROCEDURE:OGTT; PROCEDURE:Fat biopsy; RADIATION:DXA scan; PROCEDURE:MRI; PROCEDURE:1H-MRS; DRUG:Tirzepatide; DRUG:Pioglitazone
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Insulin resistance in normal weight women with diabetes compared to those with no diabetes [Baseline measures comparison between the groups]
Adipocyte function in women with normal weight diabetes as compared with those without diabetes [Baseline comparisons]
Fat storage in women with normal weight diabetes compared to those without diabetes [Baseline comparisons between the groups]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.